Drug intelligence / Profile preview

EVO200

Development stage: Unknown
Lead developer: Evofem Biosciences
Administration: Intravaginal

Overview

EVO200 is an investigational vaginal pH modulator being developed to prevent recurrent bacterial vaginosis. It aims to maintain an acidic vaginal environment that is unfavorable to pathogenic overgrowth associated with recurrent BV. In a Phase 1 dose-finding study, the highest-dose formulation reduced vaginal pH for up to seven days after a single administration. The program has received FDA Qualified Infectious Disease Product (QIDP) designation for prevention of recurrent BV. Developer: Evofem Biosciences.[9][5]

Beyond the preview

Go deeper on EVO200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVO200.

Explore the full profile